Adverse effects of therapy for ANCA-associated vasculitis.

Jennifer Turnbull; Lorraine Harper

doi:10.1016/j.berh.2009.04.002

Adverse effects of therapy for ANCA-associated vasculitis.

Jennifer Turnbull
, Lorraine Harper

Immunology and Immunotherapy

Research output: Contribution to journal › Article

40 Citations (Scopus)

Abstract

The introduction of cyclophosphamide- and prednisolone-based treatment regimens has significantly improved outcome in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. However, these regimens are nonspecific immunosuppressants associated with significant toxicity, including increased risk of infection, leucopenia, diabetes and malignancy. In addition, disease damage, particularly renal failure, increases the risk of toxicity. Improvements in disease management should include the increased awareness of treatment-related toxicity and its prevention.

Original language	English
Pages (from-to)	391-401
Number of pages	11
Journal	Best Practice & Research: Clinical Rheumatology
Volume	23
Issue number	3
DOIs	https://doi.org/10.1016/j.berh.2009.04.002
Publication status	Published - 1 Jun 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

immunosuppression
toxicity
adverse events
ANCA-associated vasculitis
infection

Access to Document

10.1016/j.berh.2009.04.002

Cite this

@article{46cee19e55494ecfb11504ee93b4d52d,

title = "Adverse effects of therapy for ANCA-associated vasculitis.",

abstract = "The introduction of cyclophosphamide- and prednisolone-based treatment regimens has significantly improved outcome in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. However, these regimens are nonspecific immunosuppressants associated with significant toxicity, including increased risk of infection, leucopenia, diabetes and malignancy. In addition, disease damage, particularly renal failure, increases the risk of toxicity. Improvements in disease management should include the increased awareness of treatment-related toxicity and its prevention.",

keywords = "immunosuppression, toxicity, adverse events, ANCA-associated vasculitis, infection",

author = "Jennifer Turnbull and Lorraine Harper",

year = "2009",

month = jun,

day = "1",

doi = "10.1016/j.berh.2009.04.002",

language = "English",

volume = "23",

pages = "391--401",

journal = "Best Practice \& Research: Clinical Rheumatology",

issn = "1532-1770",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Adverse effects of therapy for ANCA-associated vasculitis.

AU - Turnbull, Jennifer

AU - Harper, Lorraine

PY - 2009/6/1

Y1 - 2009/6/1

N2 - The introduction of cyclophosphamide- and prednisolone-based treatment regimens has significantly improved outcome in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. However, these regimens are nonspecific immunosuppressants associated with significant toxicity, including increased risk of infection, leucopenia, diabetes and malignancy. In addition, disease damage, particularly renal failure, increases the risk of toxicity. Improvements in disease management should include the increased awareness of treatment-related toxicity and its prevention.

AB - The introduction of cyclophosphamide- and prednisolone-based treatment regimens has significantly improved outcome in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. However, these regimens are nonspecific immunosuppressants associated with significant toxicity, including increased risk of infection, leucopenia, diabetes and malignancy. In addition, disease damage, particularly renal failure, increases the risk of toxicity. Improvements in disease management should include the increased awareness of treatment-related toxicity and its prevention.

KW - immunosuppression

KW - toxicity

KW - adverse events

KW - ANCA-associated vasculitis

KW - infection

U2 - 10.1016/j.berh.2009.04.002

DO - 10.1016/j.berh.2009.04.002

M3 - Article

C2 - 19508946

SN - 1532-1770

VL - 23

SP - 391

EP - 401

JO - Best Practice & Research: Clinical Rheumatology

JF - Best Practice & Research: Clinical Rheumatology

IS - 3

ER -

Adverse effects of therapy for ANCA-associated vasculitis.

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this